Dermatology NewsFDA approves IL-17A antagonist for treating psoriatic arthritisDecember 2, 2017Psoriatic ArthritisPsoriasis
Dermatology NewsTopical tapinarof heads for phase 3 in atopic dermatitis and psoriasisNovember 11, 2017PsoriasisPsoriatic ArthritisAtopic Dermatitis
Dermatology NewsUstekinumab may reduce risk of nonmelanoma skin cancerNovember 7, 2017PsoriasisPsoriatic ArthritisNonmelanoma Skin Cancer
Dermatology NewsModerate psoriasis: the new frontier for systemic therapiesNovember 6, 2017Psoriatic ArthritisPsoriasis
Dermatology NewsPsA disease activity instruments differ on residual diseaseNovember 3, 2017Psoriatic Arthritis
Dermatology NewsGuselkumab tops adalimumab for psychiatric comorbidities in psoriasisOctober 31, 2017PsoriasisPsoriatic Arthritis
Dermatology NewsPsoriasis patients face higher risk of alcohol-related death – but lower suicide riskOctober 27, 2017PsoriasisPsoriatic Arthritis
Dermatology NewsStopping anti-TNF drugs in PsA has high rebound riskOctober 26, 2017Psoriatic Arthritis
Dermatology NewsBiosimilars poised to save $54 billion over the next decadeOctober 25, 2017Psoriatic ArthritisBusiness of MedicinePsoriasisPractice Management
Dermatology NewsPsoriasis: Biologics bring potential for long-term remission off treatmentOctober 22, 2017PsoriasisPsoriatic Arthritis
Dermatology NewsHigh ‘nocebo’ effect observed when patients knowingly switch to a biosimilarOctober 18, 2017Psoriatic Arthritis
Dermatology NewsPediatric psoriasis carries sharply increased risk of selected autoimmune comorbiditiesOctober 14, 2017PsoriasisPsoriatic Arthritis
Dermatology NewsBiologic approved for moderate to severe psoriasis in adolescentsOctober 14, 2017PsoriasisPediatricsPsoriatic Arthritis
